SAN.PA - Sanofi
| Previous Close | 82.07 |
| Open | 81.22 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 81.05 - 82.08 |
| 52 Week Range | 71.74 - 85.90 |
| Volume | 1,632,568 |
| Avg. Volume | 2,366,819 |
| Market Cap | 101.794B |
| Beta (3Y Monthly) | 0.45 |
| PE Ratio (TTM) | 28.76 |
| EPS (TTM) | 2.85 |
| Earnings Date | Oct 31, 2019 |
| Forward Dividend & Yield | 3.07 (3.74%) |
| Ex-Dividend Date | 2019-05-09 |
| 1y Target Est | 82.62 |
- Yahoo Finance Video
CVS suspends sales of Zantac during safety review
Heartburn drug Zantac is facing new scrutiny after CVS pulled the products from shelves over a possible link to cancer. Yahoo Finance's Jared Blikre joins Alexis Christoforous on The Ticker to discuss.
- Yahoo Finance Video
Top Trending: Abbott and Sanofi team up to help diabetes patients, Boeing’s board expected to reconsider engineering
Top Trending: Abbott and Sanofi team up to help diabetes patients, Boeing’s board expected to reconsider engineering, and NBA's Raptors to introduce sports hijab for women.
- TipRanks
Morgan Stanley: 2 European Stocks to Overthrow the US Market Dominance
The last decade, since the financial crisis of 2008 and the subsequent Great Recession, have seen a heavy dominance of US companies in the global stock markets. American stocks have outperformed the international markets in all but two (2012, 2017) of the years since. Investment firm Morgan Stanley compared the records of the US S&P 500 with the MSCI All Country World Index (excluding the US), and noted that the American index has returned 500 basis points more, on average, than the international markets.This trend could be at the initial stages of a reversal. According to Morgan Stanley’s chief investment strategist Lisa Shalett, “We see the relative outperformance of the S&P 500 versus the MSCI ACW ex US as reaching an inflection point.” She reached this conclusion after taking a closer look at the MSCI Europe returns in comparison to the S&P 500. Shalett’s market research shows that for much of the past year, the European index has outperformed the S&P.Shalett takes the position that recent global economic disruptions – the general slowdowns, the bond yield inversion, and the fallout of the US-China trade dispute – have all been discounted in global stocks, while the relative immunity of the US economy has prevented American investors from ‘baking in’ the risks. In addition, the Federal Reserve raised rates four times in 2018, boosting the dollar against the Euro. It’s only in recent months that the Fed has begun lowering rates, and that US investors have begun to worry about the recession fears that bedeviled Europe for the last two years.In Shalett’s view, as the global economic climate grows chancier, US stocks will start to falter – while European stocks, which have already seen their losses, will stand to gain as investors seek stronger buys. Shalett says, “The pay-off from this type of positioning could be large as non-US markets are … more operationally leveraged to improvements in global growth.” In other words, now may be the time to pick up European stock, while they’re relatively cheap.We’ve used the TipRanks' Best Stocks to Buy tool to find two European-based stocks with Strong Buy ratings and endorsed by Morgan Stanley in particular. Two pharmaceutical companies fit the bill.Sanofi SA (SNY)We’ll start with Paris-based Sanofi. This $100 billion-plus pharmaceutical giant is known for a wide range of drugs on the market, including a generic epinephrine injector, Glucophage for treatment of Type 2 diabetes, and the popular insomnia treatment Ambien. Over-the-counter offerings include Maalox, the well-known antacid, and Nasacort, a nasal spray used to treat allergy-related rhinitis. In addition to the company’s array of salable pharmaceuticals, Sanofi also has an active pipeline, with 83 projects total, including 35 in Phase 3 testing or submitted for regulatory approval.Sanofi fits the Morgan Stanley profile described above, of a European stock that has baked in its recent weakness. SNY shares peaked two years ago, in October 2017, and while the share price started gaining in June of last year, it has had trouble gaining traction in the volatile market environment. That trouble has been restricted to share price, however – earnings have consistently beaten expectations since Q1 2018. The Q2 2019 report showed the widest margin, with a 10.4% beat.The company’s revenue and profits are similarly robust. The 34.5 billion Euro (US$38.4 billion) recorded in 2018 was an increase from the year before, as was the 4.7 billion Euro (US$5.23 billion) in net profits. These strong numbers come along with a 13% gain since the stock’s most recent trough, on August 5 of this year. The healthy revenues, profits, and earnings have supported a strong dividend, with a 3.75% yield and a $1.72 annualized payout. The recent gains, along with the steady income performance through a period of lower share prices, suggest a company that has met and managed the risks of current market conditions and is ready for further gains, in line with Morgan Stanley’s general thesis above.The firm’s 3-star analyst Mark Purcell agrees with that thesis, and upgraded his stance on SNY last month. He wrote to justify his Buy rating, “The company has the lowest risk growth outlook in European pharma given its lack of major patent cliffs and the largely de-risked nature of pipeline drugs in the late stages. We think Sanofi's defensive qualities position it as a key holding in the current environment…” Purcell raised his price target by 14% to 90 Euro ($100), suggesting an impressive upside of 118%. (To watch Purcell's track record, click here)Purcell was not the only analyst to upgrade SNY recently. Guggenheim’s Seamus Fernandez also bumped the stock up to a Buy rating. Fernandez noted, “We believe that emerging markets growth should help stabilize the large established products and overall diabetes franchises and think that vaccines business growth looks sustainable.” His 96 Euro ($107) price target implies room for 133% growth to the stock.SNY’s recent reviews include 4 buys – and nothing negative, giving this stock a Strong Buy on the consensus. Shares sell for $45.48, and the average price target of $52 suggests a 14% upside potential. (See Sanofi stock analysis on TipRanks)GW Pharmaceuticals (GWPH)GW is a unique. It’s a small-cap international pharmaceutical company, with a total market capitalization of just $3.8 billion, and it’s also an early adopter in the cannabis industry. Like many cannabis-related companies, GW’s earnings are upside down. Market analysts expect that this will change, now that GW has two drugs post-approval.The company specializes in developing medical uses for the non-psychoactive CBD compound. The two new drugs it has derived from this are Sativex, an oral spray used to treat chronic pain and muscle spasticity in multiple sclerosis, and Epidiolex, an orally administered liquid solution for use in treating two rare forms of early-childhood epilepsy.GW has high hopes for both drugs, and early indications are bearing those hopes out. Epidiolex has been on the US markets for two quarters now; in its second full quarter of sales, it was expected to reach $45 million and actually hit $68 million. It was a clear win for GW Pharma, and has helped to bolster the company’s prospects. Morgan Stanley used the sales beat to support a Buy rating and a 2% price target bump to $238.Morgan Stanley analyst David Lebovitz noted that the strong Epidiolex sales indicated a FY2019 estimate for the drug of $291 million, a steep increase from the original forecast of $165 million. In an update note last month, Lebovitz added, “Mgt. announced that the European Commission (EC) has approved EPIDYOLEX® (spelled EPIDIOLEX in the US) for use as adjunctive therapy of seizures associated with Lennox Gastaut syndrome (LGS) or Dravet syndrome, for patients 2 years of age and older. The approval is as... The approval is valid in all 28 countries of the European Union.” Lebovitz’s $238 price target on GWPH indicates confidence in a 95% upside potential.The analyst outlook on GWPH lines up with Lebovitz. Like SNY above, it is unanimous. GWPH has a Strong Buy consensus, based on 10 buy ratings set in the last three months. The stock’s $221 average price target suggests a robust 75% upside from the current trading price of $121. (See GW Pharmaceuticals stock analysis on TipRanks)
- GlobeNewswire
Sanofi: information concerning the total number of voting rights and shares, September 2019
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article.
- Reuters
TIMELINE-Popular heartburn medicine Zantac pulled off store shelves
The U.S. Food and Drug Administration and international health authorities are investigating the safety of Zantac heartburn medicine, also sold generically as ranitidine, after finding a probable cancer-causing impurity in the drug. Ranitidine is the newest drug in which presence of cancer causing impurities have been found. Glaxo Holdings Ltd, now a part of GlaxoSmithKline PLC , receives its first U.S. FDA approval for Zantac as a short-term treatment of a common form of ulcers.
- Reuters
UPDATE 2-Star French banker Pigasse resigns from Lazard
French banker Matthieu Pigasse is to leave Lazard after 17 years to pursue a new entrepreneurial project, an exit that will see the firm lose one of its biggest rainmakers. For Lazard, Pigasse has led the world's largest sovereign debt restructurings in Greece, Argentina and Ukraine, as well as multi-billion mergers such as those between Unibail-Rodamco and Westfield, Sanofi and Boehringer Ingelheim, Safran and Zodiac. "I am excited to begin my next chapter beyond investment banking in a new entrepreneurial project," Lazard cited Pigasse as saying.
- Reuters
Sanofi pulls Zantac from U.S. and Canada after carcinogen found
Sanofi SA said on Friday it would recall popular heartburn medicine Zantac in the United States and Canada, after the medicines were linked with a probable cancer-causing impurity. The French drugmaker said it was working with health authorities to determine the level and extent of the recall, which it called a precautionary measure being taken due to possible contamination with a substance called N-nitrosodimethylamine (NDMA). U.S. and European health regulators said last month they were reviewing the safety of ranitidine, which is commonly sold as Zantac and its generic alternatives, after an online pharmacy called Valisure notified them that it had found impurities in the drugs.
- Reuters
UPDATE 2-Sanofi pulls Zantac from U.S. and Canada after carcinogen found
Sanofi SA said on Friday it would recall popular heartburn medicine Zantac in the United States and Canada, after the medicines were linked with a probable cancer-causing impurity. The French drugmaker said it was working with health authorities to determine the level and extent of the recall, which it called a precautionary measure being taken due to possible contamination with a substance called N-nitrosodimethylamine (NDMA). Sanofi has sold over-the-counter Zantac in the U.S. and Canada since 2017.
- Reuters
Sanofi to pull heartburn drug Zantac in US, Canada
Sanofi SA said on Friday it would recall popular heartburn drug Zantac in the United States and Canada, the latest drugmaker to pull the medicine, which has been linked with a probable cancer-causing impurity. Sanofi added that it was working with health authorities to determine the level and extent of the recall. Zantac, whose generic versions are known chemically as ranitidine, is the latest drug in which cancer-causing impurities have been found.
- PR Newswire
Sanofi opens its first digitally-enabled, continuous manufacturing facility; ushers in next generation of biotech manufacturing
PARIS, Oct. 15, 2019 /PRNewswire/ -- Sanofi today celebrates the inauguration of its new digital manufacturing facility in Framingham, Massachusetts, marking one of the world's first digital facilities using intensified, continuous biologics production technology. The new facility features leading-edge technology that connects the production process with research and development, paving the way for improved commercialization of important new medicines for patients. This facility accelerates the recent transformation of Sanofi's Industrial Affairs organization to focus on biologics-based therapies, in line with the transformation of the company's R&D pipeline.
- Insider Monkey
Hedge Funds Are In Wait And See Mode With Sanofi (SNY)
Hedge funds run by legendary names like George Soros and David Tepper make billions of dollars a year for themselves and their super-rich accredited investors (you’ve got to have a minimum of $1 million liquid to invest in a hedge fund) by spending enormous resources on analyzing and uncovering data about small-cap stocks that the […]
- TipRanks
Wall Street Loves These “Strong Buy” Dividend Stocks
Stock go up, investor happy. Stock go down, investor... sad?Probably. In fact, we'd go so far as to say that's probably the ordinary reaction an investor has to a decline in the share price of a stock he or she owns -- but not all the time.You see, if the stock is question is a dividend stock, even a decline in stock price can be offset by the value of the dividend you're being paid to own it. What's more, because a stock's dividend yield is calculated by dividing the dividend amount by the stock price, the lower the stock price falls, the bigger the dividend yield becomes -- making the stock increasingly attractive to other dividend investors, and providing a backstop that can prevent the stock falling further!So how do you find great dividend stocks, popular on Wall Street, and attractive to dividend investors?Using the Stock Screener at TipRanks, you can screen for stocks rated "strong buy" by Wall Street analysts, and screen, too, for stocks paying better-than-average dividend yields. Combine these two attributes, and voila! You've got a great dividend stock candidate. Here are three of them:Sanofi (SNY) One of Europe's largest drugmakers, Paris-based Sanofi boasts a market capitalization north of $112 billion, more than $40 billion in annual sales, and net profits approaching $4 billion. Sanofi stock's a great cash generator as well, throwing off nearly $6.3 billion in cash over the last 12 months, enabling it to pay a market-beating dividend yield of 3.9%.Just recently, Morgan Stanley analyst Mark Purcell upgraded Sanofi shares to "overweight," calling the stock a "defensive" play in an uncertain market. According to Purcell, the stock is "largely de-risked" -- indeed, the analyst says Sanofi has the lowest risk growth outlook of any European Big Pharma stock, due to a lack of big drugs losing patent protection in the near future (the dreaded "patent cliff"), and a pipeline of new drugs in late-stage clinical trials that could soon come to market.Whereas the consensus on Wall Street is that Sanofi stock is worth $52 per share, Purcell thinks Sanofi could go all the way to ... $98 a share! (To watch Purcell's track record, click here)"We argue that new CEO Paul Hudson inherits significant optionality to unlock shareholder value alongside the recent CFO and CSO appointments. The management team can draw on their shared experience from the strategic transformations of AstraZeneca and Novartis, the new chapter of innovation at Roche and the cost discipline of Peugeot. The evolution of the GSK equity story, with which Sanofi has much in common, albeit with greater balance sheet flexibility and lower patent risk, offers a further yardstick for investors, we believe. We explore potential strategic options that could in theory help to close the 15% relative P/E multiple discount," Purcell said.Sanofi stock hasn't moved much over the past year, up less than 4%. Regardless, Wall Street loves Sanofi stock, rating it "strong buy" on average, and with a $52 price target implying 14.5% upside from today's prices. Factor in the dividend, and you're pushing 18.5% potential profit. (See Sanofi stock analysis on TipRanks)Merck (MRK) But you needn't travel all the way to Europe to find an attractive drug stock paying a big dividend. Right here at home, Kenilworth, New Jersey-based Merck & Co. pays its shareholders a very respectable 2.7% dividend yield. (The average stock on the S&P 500 is only paying 2%).Recently, Merck presented more positive data at ESMO supporting the use of Keytruda + chemo to treat neoadjuvant/adjuvant TNBC. These data, along with other data presented at ESMO, like BMY's (NC) Merck-227 data and the Lynparza ovarian data, support MRK's leadership in oncology.Morgan Stanley analyst David Risinger commented, "KN-522 demonstrated an impressive pathologic complete response (pCR), improving on results from its earlier exploratory KN-173 trial. On another key efficacy metric, event free survival (EFS), the trend to 18mo looks quite favorable but the trial’s discussant urged a measure of caution in over-interpreting the findings, saying data were too early still and need to mature. The reason for caution is that discontinuation rates were ~2x for Keytruda vs placebo (PBO), raising the specter that longer-term survival curves may look different than shown at the first, early look, if too many patients are stopping therapy prematurely. The discussant also reminded that certain immune-related adverse events would likely be permanent, implying a more definitive calculation of risk:benefit is warranted, but this is not yet possible from the preliminary data set."As a result, Risinger reiterated an Overweight rating on MRK stock with $90 price target, which implies nearly 7% upside from current levels. (Watch Risinger's track record, click here)Overall, the consensus targets on the Street see Merck shares rising as high as $100 per share over the next 12 months, 18% above current levels. (See Merck stock analysis on TipRanks)Verizon (VZ) Switching gears now from the somewhat esoteric world of biotech to a company we're all very familiar with, Verizon is our final stock to look at in today's column -- and for good reason.Investors have long viewed the telecom industry as a happy hunting ground for stocks paying robust dividends, and Verizon, which pays 4.2%, is no exception. In fact, Verizon has raised its dividend for 13 years in a row, with its latest dividend hiking coming just last month. At 4.2%, Verizon's dividend is now more than twice the market average.One analyst who likes Verizon more than most is Oppenheimer's Timothy Horan, who in August upgraded Verizon shares to "outperform" with a $70 price target implying better than 16% upside (and better than 20% with the dividend added in). Horan believes that Verizon will be an early beneficiary of the telecommunications industry's move to 5G wireless technology. And anticipating customer defections from T-Mobile and Sprint once those two companies merge, Horan predicts that Verizon will also benefit from customer "churn" at this wireless rival. (To watch Horan's track record, click here)Overall, Wall Street loves the stock, giving Verizon "strong buy" ratings by and large. Granted, with a consensus price target of "only" $65, most analysts don't see a huge amount of upside in the stock -- only about 9%. But if you add in the dividend yield, the potential profit on this one exceeds 13%, and maybe even more.Topping it all off, with a P/E of less than 16, Verizon's not just the biggest dividend payer on today's list of highly-rated dividend stocks -- it's also the cheapest. (See Verizon stock analysis on TipRanks)
- Simply Wall St.
Sanofi (EPA:SAN) Has A Pretty Healthy Balance Sheet
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
- GlobeNewswire
Sanofi : Availability of the Pre-quarterly Results Communication
As for each quarter, Sanofi prepared this document to assist in the financial modeling of the Group's quarterly results. Sanofi's third-quarter 2019 results will be published on October 31, 2019. Sanofi is dedicated to supporting people through their health challenges.
- GlobeNewswire
Sanofi : New England Journal of Medicine publishes data showing improved survival with Jevtana® (cabazitaxel) over second androgen receptor-targeted agent in metastatic castration-resistant prostate cancer
New England Journal of Medicine publishes data showing improved survival with Jevtana® (cabazitaxel) over second androgen receptor-targeted agent in metastatic.
- CBS MoneyWatch
CVS pulls Zantac and its generic brand over possible cancer link
The FDA said people shouldn't panic, but suggests switching to another over-the-counter drug while the agency tests more samples
CNW GroupSanofi Canada receives Gold-Level Parity Certification
LAVAL, QC, Sept. 26, 2019 /CNW Telbec/ - Sanofi Canada is pleased to announce that the company has reached a great milestone: our first Parity Certification from the Women in Governance organization. This certification means that Sanofi Canada has taken its place among notable Canadian companies that strive towards gender parity.
- Bloomberg
After Shingles Standout, Glaxo Hunts for the Next Vaccines
(Bloomberg) -- GlaxoSmithKline Plc is taking aim at a virus that causes serious lung infections and kills tens of thousands of children each year, hoping to replicate the success of its last blockbuster vaccine.Experimental shots targeting respiratory syncytial virus, or RSV, are the top pipeline priority for Glaxo’s vaccines unit, Emmanuel Hanon, its research and development head, said in an interview. Glaxo plans to move those vaccines into the final stage of testing by the end of 2020, he said.“This represents a massive opportunity, provided we can deliver,” Hanon said.Glaxo isn’t the only company racing to deliver an RSV vaccine, a goal that has eluded scientists for about half a century. Drugmakers including Johnson & Johnson and Sanofi are also working on potential shots against the virus, which is estimated to cause as many as 200,000 deaths a year across the globe.The vaccine is one of the keys to the British drugmaker’s ambitions to build on Shingrix, the shingles shot forecast to generate sales of about $1.8 billion this year. While Glaxo’s pharma unit garners most of the attention, vaccines are set to play a bigger role as the company moves ahead with plans to separate its consumer health division.Glaxo is keen to expand in the realm of therapeutic vaccines, used after an infection occurs, and to speed up the development of new shots, a journey that can take 15 years, Hanon said. The company sees an opportunity to do it in half as much time partly by harnessing new technologies that enhance the immune system’s response to vaccines.“That’s our ambition,” he said. “Fifteen years is too long.”Next StoryVaccines have already helped Glaxo counter generic competition for Advair, the company’s aging mega-drug for asthma. The unit’s sales climbed 25% in the first half of the year to 3.1 billion pounds ($3.8 billion). The drugmaker is providing a vaccines update at an event for investors Thursday. Glaxo shares rose 1.8% in London trading. “The business is of increasing significance for them,” said Emmanuel Papadakis, an analyst at Barclays in London. Investors will likely focus on its plans to expand Shingrix capacity and “the next story on the pipeline side.”Drugmakers appear to be making progress in pursuit of an RSV shot. Sanofi’s new Chief Executive Officer Paul Hudson earlier this month cited the French company’s experimental vaccine as one of its most promising opportunities.Almost all children get an RSV infection by the time they are two years old, according to the U.S. Centers for Disease Control and Prevention. While it mostly causes mild, cold-like illnesses, it can lead to more serious problems, such as pneumonia and bronchiolitis, infections of the lungs and airways.Among therapeutic vaccines, Glaxo is also developing a product to prevent a lung disease called chronic obstructive pulmonary disease from worsening due to bacteria. The company hopes to have data to show the vaccine works by the second half of next year, Hanon said.(Updates with other drugmakers working on RSV vaccine in fourth paragraph.)To contact the reporter on this story: James Paton in London at jpaton4@bloomberg.netTo contact the editors responsible for this story: Eric Pfanner at epfanner1@bloomberg.net, Marthe FourcadeFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.
- Barrons.com
Sanofi and Regeneron Stocks Will Gain Because Dupixent Collaboration is Big, Analysts Say
Guggenheim analysts upgraded both Sanofi and Regeneron in part because of optimism about an antibody drug that treats a range of diseases on which the two companies have collaborated.
- Investor's Business Daily
Stocks Reverse Lower On Trade Fears, But Small Caps Lose Less
Stock indexes reversed lower Friday afternoon, as the market for a second straight day seemed unable to hold early advances. The S&P; 500 today and other indexes fell sharply at 1:15 p.m. ET.
- GlobeNewswire
Sanofi : CHMP recommends approval of Dupixent® (dupilumab) for severe chronic rhinosinusitis with nasal polyposis
September 20, 2019 – The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Dupixent® (dupilumab) in a third indication. The CHMP recommended Dupixent be approved as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe chronic rhinosinusitis with nasal polyposis (CRSwNP) for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. If approved, Dupixent would be the first biologic medicine available in the European Union (EU) to treat these patients.
- Reuters
Factbox: Britain's insulin providers prepare for Brexit fallout
With Britain sourcing the vast majority of the insulin needed by its 1 million diabetics from overseas, its biggest providers have had to restructure their supply chains in case a chaotic Brexit disrupts the normal arteries of trade. Below are some of the steps Novo Nordisk, Eli Lilly and Sanofi have taken to prepare for Britain's departure from the European Union on Oct. 31. - All three firms have increased the amount of insulin they are holding inside the country in case a no-deal Brexit leads to customs checks and lengthy delays at Britain's biggest ports of Dover and Folkestone.
